CAFs drive resistance in EGFR-mutant NSCLC by promoting EMT and secreting resistance-inducing factors such as HGF, IL-6, and kynurenine, activating pro-survival pathways in cancer cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.